POSEIDON: durvalumab +/- tremelimumab + chemo in 1L mNSCLC скачать в хорошем качестве

POSEIDON: durvalumab +/- tremelimumab + chemo in 1L mNSCLC

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, reviews data presented from the POSEIDON study. POSEIDON (NCT03164616) is a randomized, open-label, Phase III study evaluating durvalumab +/- tremelimumab in combination with investigator-choice chemotherapy regimens as first-line treatment for squamous or non-squamous metastatic non-small cell lung cancer (mNSCLC). Durvalumab +/- tremelimumab in combination with chemotherapy demonstrated statistically significant improvements in both progression-free survival (PFS) and overall survival (OS) versus chemotherapy alone in patients with mNSCLC. Additionally, PFS was significantly improved in patients treated with with durvalumab plus chemotherapy versus chemotherapy alone, while a positive trend for OS did not reach statistical significance. The safety profile was similar across all three arms, with no new safety signals identified. Durvalumab +/- tremelimumab in combination with chemotherapy may represent a new first-line treatment option for mNSCLC. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.